Navigation Links
New Topical Painkiller Relieves Severe Pain in Minutes

ENCINO, Calif., April 13 /PRNewswire/ bluMjk (pronounced "Blue Magic"), a new over-the-counter topical painkiller, uses patent pending skin and nerve penetrating technology to relieve the majority of moderate to severe pain experienced by most pain sufferers. Within minutes of a topical application, bluMjk restores pain nerve fibers to their natural resting state, which eliminates the sensation of pain. R & S Research developed this new penetrating technology to quickly and safely deliver the active ingredient, salicylate, deep into the skin and target nerve cells without any side- effects.

Salicylate has historically been an effective oral pain reliever acting as a Non-Steroidal Anti-Inflammatory Drug, with the same mode of action as aspirin or ibuprofen. Topically, applied bluMjk works much faster and much more powerfully to relieve moderate to severe pain in a wide variety of pain conditions.

The unique combination of all natural ingredients which comprise the carrier system of this new formulation bring the active ingredient, salicylate, through the layers of the skin and then through the cell membrane of the nerves that transmit the sensation of pain to the brain. Because of the speed with which bluMjk works the R & S Research team concluded the effect of bluMjk on these pain nerves is to shut off their output and restore them to a resting state. Because bluMjk is not an anesthetic it has no effect on any other nerves, and sensations of touch, pressure, hot, cold, etc are unaffected by this medication. Since the effect of bluMjk takes place where the pain originates there is no effect on the brain and therefore no chance of habituation or addiction. bluMjk is as powerful as a narcotic and as safe as aspirin.

bluMjk has been used in a large variety of clinical pain syndromes effectively, including tension and migraine headaches, both osteo and rheumatoid arthritis, various nerve inflammations including herpes zoster (shingles), and has been found to be effective in almost every type of peripheral pain including muscle and joint pain of almost any origin. Interestingly, this medication has been effective in some extremely hard to treat conditions such as TemperoMandibular Joint disease and the chronic severe intractable nerve pain that may occur in some cases of shingles. One of the most resistant pain conditions afflicting the human race, Reflex Sympathetic Dystrophy or CRPS, has been shown to be responsive to bluMjk on an anecdotal basis.

Pain relief after using bluMjk typically lasts four to six hours. Clearly, the quality of life of many pain sufferers can now take a turn for the better.


R & S Research, LLC, located in Encino, CA, is a manufacturer and wholesaler of over the counter pharmaceuticals based on the company's proprietary skin and cell membrane penetrating technologies. It is dedicated to the mission of developing unique products that have no existing counterparts. It is doctor owned and operated.

     Galen Weaver, Media Relations
     R & S Research

SOURCE R & S Research
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Topical Dermatological Product Development in the USA Workshop to Be Held on June 4, 2009 in East Brunswick, New Jersey, USA
2. Chronic Pain Sufferers Report Relief: DRJ Group Teams With Adult Foster Care Facilities to Evaluate Effectiveness of Stopain Topical Analgesic
3. Topical Spray Helped Men With Premature Ejaculation
4. Perrigo Announces FDA Approval for Sulfacetamide Sodium Topical Suspension USP, 10% (Lotion)
5. Global Warming Expected to Spike Pollen and Spring Allergies - New Drug-Free Topical Gels Boost Hope for Allergy Sufferers
6. Study Shows Nonprescription LCD Topical Solution is More Effective than Prescription-Strength Calcipotriol Cream for Moderate Plaque Psoriasis
7. The Texas Institute of Dermatology Team Finds Easy-to-Apply, Topical Drug Just as Good as Injectable Compound for a Disfigurating Skin Infection
8. NanoBio to Announce Key Clinical and Preclinical Data on Its Topical Anti-infective Lotions at AAD 2009
9. American Academy of Dermatology Issues New Guidelines For The Management of Psoriasis With Topical Therapies
10. High and Super-High Potency Topical Corticosteroids Will Remain Decision Resources Clinical Gold Standard Through 2017 for the Treatment of Atopic Dermatitis
11. Galderma Wins FDA Approval for Vectical(TM) Ointment, a Novel Topical Therapy for Mild-to-Moderate Plaque Psoriasis
Post Your Comments:
(Date:11/24/2015)... ... November 24, 2015 , ... The ... waive paid entry and parking fees at several of their most popular properties, ... Great Barrington in support of REI’s Black Friday #OptOutside Campaign. The Trustees encourage ...
(Date:11/24/2015)... ... November 24, 2015 , ... In response to recent news ... deaths from prescription opioids in the United States grew 400 percent between 1999 and ... opioids were involved in 37 percent of all fatal drug overdoses. (1) , While ...
(Date:11/24/2015)... ... November 24, 2015 , ... Cancer patients, survivors, caregivers, ... at a live taping of the next CURE Connections® video series ... Cancers 2015 Symposium at Georgetown University Hotel & Conference Center in Washington, D.C. ...
(Date:11/24/2015)... AL (PRWEB) , ... November 24, 2015 , ... American ... announced today the opening of a holiday pop-up clinic located in Metro Atlanta’s North ... needs in a new and different way. The location is scheduled to operate through ...
(Date:11/24/2015)... ... November 24, 2015 , ... With Thanksgiving right around the ... safety tips to help protect your family and vehicle. , According to the National ... Thanksgiving holiday weekend. Amica is sharing the following safety tips from the NHTSA: ...
Breaking Medicine News(10 mins):
(Date:11/24/2015)... 24, 2015  Figure 1, a free mobile-first network ... cases, has launched a new completely redesigned web version ... allows radiologists, who work primarily on a desktop, to ... with its radiologist user base, Figure 1 is hosting ... North America (RSNA) Annual Meeting. ...
(Date:11/24/2015)... , Nov. 24, 2015  Family Rentals, a ... announced the launch of their newly designed, mobile-responsive ... --> Logo ... --> --> Now, renting essential ... and vacation, just got a whole lot easier ...
(Date:11/24/2015)... The uptake of recently approved and pipeline premium products for Type 1 ... 2021, says GBI Research . --> ... Diabetes Mellitus (T1DM), will be a key driver of market growth to ... The uptake of recently approved and pipeline premium products for Type ... to 2021, says GBI Research . ...
Breaking Medicine Technology: